Related Experiment Videos
Bromocriptine reduces growth hormone in acromegaly
Archives of Internal Medicine
|June 1, 1986
Summary
Bromocriptine mesylate significantly reduced serum growth hormone (GH) levels in acromegaly patients. Both 24-hour profiles and glucose tolerance tests showed this therapeutic effect, indicating bromocriptine
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Acromegaly is a disorder caused by excess growth hormone (GH).
- Bromocriptine mesylate is a dopamine agonist used in treating endocrine disorders.
Purpose of the Study:
- To evaluate the efficacy of bromocriptine mesylate in reducing serum GH levels in acromegaly patients.
- To compare GH levels during bromocriptine treatment versus withdrawal using 24-hour profiles and oral glucose tolerance tests (GTT).
Main Methods:
- Ten acromegaly patients underwent serum GH level assessments.
- Measurements were taken during three periods: on bromocriptine (P1), off bromocriptine (P2), and back on bromocriptine (P3).
- Assays included a 24-hour GH profile and a 75-g oral glucose tolerance test (GTT).
Main Results:
- Mean serum GH levels were significantly lower during bromocriptine treatment (P1 and P3) compared to withdrawal (P2) in both 24-hour profiles and GTTs.
- Individual patient data showed significant GH reductions with bromocriptine therapy.
- Circadian variation in GH levels was observed both with and without bromocriptine therapy.
Conclusions:
- Bromocriptine mesylate effectively reduces serum GH levels in patients with acromegaly.
- Both 24-hour GH profiling and GTT are reliable indicators of bromocriptine's therapeutic response in individual acromegaly patients.